Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.4
Journals
Medicina
Special Issues
Clinical Experience with Radiation Therapy in Prostate Cancer
share announcement

Clinical Experience with Radiation Therapy in Prostate Cancer

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: closed (20 November 2023) | Viewed by 4866

Special Issue Editors

Dr. Giuseppe Ferrera

E-Mail
Guest Editor
Radiation Oncology Unit, ARNAS Civico Hospital, Palermo, Italy
Interests: hypofractionation; stereotactic radiotherapy; oligometastases; prostate cancer; lung cancer; pediatric radiotherapy
Dr. Corrado Spatola

E-Mail Website
Guest Editor
Department of Medical Surgical Sciences and Advanced Technologies “G.F. Ingrassia” – U.O. Radioterapia Oncologica, A.O.U. Policlinico “G. Rodolico—San Marco” Catania, Via Santa Sofia 78, 95123 Catania, Italy
Interests: ocular oncology; head and neck cancer; uveal melanoma; radiation therapy; proton therapy; integrated radio-chemotherapy
Special Issues, Collections and Topics in MDPI journals
Dr. Stefano Pergolizzi

E-Mail Website
Guest Editor
Department of Biomedical and Dental Sciences, and Morphological, and Functional Images, University of Messina, Messina, Italy
Interests: radiation; oncology; lung cancer; medical oncology; chemotherapy radiotherapy; radiation oncology; dosimetry; radiotherapy physics; radiation dosimetry

Special Issue Information

Dear Colleagues,

Prostate cancer represents the most common tumor in the male population, and radiation therapy has traditionally played a main role in the management of every phase of the natural history of the disease, from localized prostate cancer to metastatic dissemination.

In recent years, we are witnessing a continuous increase in knowledge from both a technological and biological perspective; with regard to the former, next-generation imaging with new metabolic tracers allows clinicians to detect the real tumor burden with increased sensitivity and specificity, and new hybrid linear accelerators equipped with on-board MR imaging enable refined accuracy for treatment planning and delivery. Additionally, a further source of knowledge is expected to be derived from applications of artificial intelligence.

From a biological point of view, in localized disease, the radiobiological properties of prostate cancer have led clinicians to explore all the declinations of altered fractionation schedules with an improved therapeutic ratio for both patients and facilities. At the same time, our scientific community is gaining a deeper understanding of the biological patterns of metastatic disease, with improved outcomes provided by metastasis-directed treatments, also in combination with new systemic therapies such as second-generation anti-androgens or PARP inhibitors.

Given the high incidence of this tumor and the key role of radiotherapy in all the settings of prostate cancer, Medicina is launching a Special Issue entitled “Clinical Experience with Radiation Therapy in Prostate Cancer” with the aim to collect up-to-date experiences and detailed overviews regarding the recent advancements in the management of this disease.

In this respect, we encourage the submission of original research studies focused on the role of radiotherapy in every phase of the natural history of the disease; in addition, we welcome literature reviews aiming to collect the available evidence on clinical issues that still remain a matter of debate in order to provide a comprehensive overview of the potential applications of radiation therapy in this scenario.

Dr. Giuseppe Ferrera
Dr. Corrado Spatola
Dr. Stefano Pergolizzi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Keywords

  • prostate cancer
  • stereotactic radiotherapy
  • oligometastases
  • hypofractionation
  • localized prostate cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 2146 KiB  
Article
Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience
by Francesco Cuccia, Maria Tamburo, Antonio Piras, Gianluca Mortellaro, Arianna Iudica, Antonino Daidone, Manuela Federico, Valentina Zagardo, Gianluca Ferini, Francesco Marletta, Corrado Spatola, Ivan Fazio, Sergio Filosto, Stefano Pergolizzi and Giuseppe Ferrera
Medicina 2023, 59(8), 1442; https://doi.org/10.3390/medicina59081442 - 9 Aug 2023
Cited by 3 | Viewed by 2095
Abstract
Background: The favorable role of SBRT for lymph-nodal oligometastases from prostate cancer has been reported by several retrospective and prospective experiences, suggesting a more indolent natural history of disease when compared to patients with bone oligometastases. This retrospective multicenter study evaluates the outcomes [...] Read more.
Background: The favorable role of SBRT for lymph-nodal oligometastases from prostate cancer has been reported by several retrospective and prospective experiences, suggesting a more indolent natural history of disease when compared to patients with bone oligometastases. This retrospective multicenter study evaluates the outcomes of a cohort of patients treated with stereotactic body radiotherapy for lymph-nodal oligometastases. Methods: Inclusion criteria were up to five lymph-nodal oligometastases detected either with Choline-PET or PSMA-PET in patients naïve for ADT or already ongoing with systemic therapy and at least 6 Gy per fraction for SBRT. Only patients with exclusive lymph-nodal disease were included. The primary endpoint of the study was LC; a toxicity assessment was retrospectively performed following CTCAE v4.0. Results: A total of 100 lymph-nodal oligometastases in 69 patients have been treated with SBRT between April 2015 and November 2022. The median age was 73 years (range, 60–85). Oligometastatic disease was mainly detected with Choline-PET in 47 cases, while the remaining were diagnosed using PSMA-PET, with most of the patients treated to a single lymph-nodal metastasis (48/69 cases), two in 14 cases, and three in the remaining cases. The median PSA prior to SBRT was 1.35 ng/mL (range, 0.3–23.7 ng/mL). Patients received SBRT with a median total dose of 35 Gy (range, 30–40 Gy) in a median number of 5 (range, 3–6) fractions. With a median follow-up of 16 months (range, 7–59 months), our LC rates were 95.8% and 86.3% at 1 and 2 years. DPFS rates were 90.4% and 53.4%, respectively, at 1 and 2 years, with nine patients developing a sequential oligometastatic disease treated with a second course of SBRT. Polymetastatic disease-free survival (PMFS) at 1 and 2 years was 98% and 96%. Six patients needed ADT after SBRT for a median time of ADT-free survival of 15 months (range, 6–22 months). The median OS was 16 months (range, 7–59) with 1- and 2-year rates of both 98%. In multivariate analysis, higher LC rates and the use of PSMA-PET were related to improved DPFS rates, and OS was significantly related to a lower incidence of distant progression. No G3 or higher adverse events were reported. Conclusions: In our experience, lymph-nodal SBRT for oligometastatic prostate cancer is a safe and effective option for ADT delay with no severe toxicity. Full article
(This article belongs to the Special Issue Clinical Experience with Radiation Therapy in Prostate Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 370 KiB  
Review
Hypofractionated Radiotherapy in Localized, Low–Intermediate-Risk Prostate Cancer: Current and Future Prospectives
by Maria Chiara Lo Greco, Giulia Marletta, Giorgia Marano, Alessandro Fazio, Emanuele Buffettino, Arianna Iudica, Rocco Luca Emanuele Liardo, Roberto Milazzotto, Pietro Valerio Foti, Stefano Palmucci, Antonio Basile, Francesco Marletta, Francesco Cuccia, Giuseppe Ferrera, Silvana Parisi, Antonio Pontoriero, Stefano Pergolizzi and Corrado Spatola
Medicina 2023, 59(6), 1144; https://doi.org/10.3390/medicina59061144 - 14 Jun 2023
Cited by 2 | Viewed by 2365
Abstract
At the time of diagnosis, the vast majority of prostate carcinoma patients have a clinically localized form of the disease, with most of them presenting with low- or intermediate-risk prostate cancer. In this setting, various curative-intent alternatives are available, including surgery, external beam [...] Read more.
At the time of diagnosis, the vast majority of prostate carcinoma patients have a clinically localized form of the disease, with most of them presenting with low- or intermediate-risk prostate cancer. In this setting, various curative-intent alternatives are available, including surgery, external beam radiotherapy and brachytherapy. Randomized clinical trials have demonstrated that moderate hypofractionated radiotherapy can be considered as a valid alternative strategy for localized prostate cancer. High-dose-rate brachytherapy can be administered according to different schedules. Proton beam radiotherapy represents a promising strategy, but further studies are needed to make it more affordable and accessible. At the moment, new technologies such as MRI-guided radiotherapy remain in early stages, but their potential abilities are very promising. Full article
(This article belongs to the Special Issue Clinical Experience with Radiation Therapy in Prostate Cancer)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop